ClinicalTrials.gg
CompletedNCT03802786Updated Aug 11, 2020

Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects

A Phase 1 interventional study of Imeglimin in Hepatic Impairment, sponsored by Poxel SA. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-11.

Sponsored by Poxel SA · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a Phase 1, single-centre, open-label, parallel-group study in subjects with moderate hepatic impairment and subjects with normal hepatic function. Child-Pugh (CP) scoring will be used to determine hepatic impairment.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • pharmacokinetics
03

In context

Lead sponsor

Poxel SA is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Caucasian
  • :18.0 and 40.0 kg/m2 and weight ≥50 kg.
  • Stable hepatic impairment or normal hepatic function for healthy volunteer
  • No findings from medical history, physical examination, 12-lead , vital sign measurements, and clinical laboratory evaluations (Subjects with moderate hepatic impairment may have medical findings consistent with their hepatic dysfunction)
  • Females will not be pregnant or lactating, and females of and males will agree to use
  • signature

Exclusion Criteria:

  • Clinically relevant abnormal findings at the screening assessment
  • Severe adverse reaction to any drug or sensitivity to the trial medication or its componentsClinically significant vital signs outside the acceptable range at screening
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs
  • Drug or alcohol abuse
  • Positive test
  • Smoking more than 10 cig/day
  • Participation in other clinical trials of unlicensed or prescription medicines

Exclusion criteria for healthy volunteer

  • Positive test for , HBC
  • less than 90 mL/min/1.73 m2
  • liver diseases

Exclusion criteria for hepatic impaired

  • eGFR less than 80 mL/min/1.73 m2
  • Hepatic impairment due to non liver disease
  • History of hepatocellular carcinoma or acute liver disease
  • CLinically significant change in liver disease status within 6 months
  • ascites
  • encephalopathy grade III or IV
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Moderate hepatic impairment

    Single dose of Imeglimin

    Drug: Imeglimin

  • Experimental
    Normal hepatic function

    Single dose of Imeglimin

    Drug: Imeglimin

Interventions

  • Single administration dose of imeglimin

06

What researchers measure

Primary outcomes

  1. PK parameters of imeglimin

    Cmax: peak plasma concentration after dosing

    Time frame: At Day 1

Secondary outcomes

  1. PK parameters of imeglimin

    AUC last:area under the concentration-time curve

    Time frame: From day 1 to day 2

  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Incidence of Treatment-Emergent Adverse Events

    Time frame: From day 1 to day 7

07

Study locations

1 site
  • Apex
    Munich, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Jul 2019, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2019
First posted
Jan 14, 2019
StartActual
Nov 6, 2018
Primary completionActual
Jul 3, 2019
CompletionActual
Jul 8, 2019
Last update
Aug 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03802786
Lead sponsor
Poxel SA
Responsible party
Sponsor
First posted
Jan 14, 2019
Start date
Nov 6, 2018
Primary completion
Jul 3, 2019
Completion
Jul 8, 2019
Last update
Aug 11, 2020

Study contacts

Clémence Chevalier
study director · Poxel SA

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imeglimin

Start the discussion